Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

PloS one - 1 Jan 2017

Blagoev Krastan B, Wilkerson Julia, Burotto Mauricio, Kim Chul, Espinal-Domínguez Edward, García-Alfonso Pilar, Alimchandani Meghna, Miettinen Markku, Blanco-Codesido Montserrat, Fojo Tito

Abstract excerpt

Emergence of tumor resistance to an anti-cancer therapy directed against a putative target raises several questions including: (1) do mutations in the target/pathway confer resistance? (2) Are these mutations pre-existing? (3) What is the relative fitness of cells with/without the mutation? We addressed these questions in patients with metastatic colorectal cancer (mCRC). We conducted an exhaustive review of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Genetic Drift

Share to Panitumumab

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 28981524
DOI: 10.1371/journal.pone.0175484
PMCID: PMC5628783

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.PMID 28981524Read ↗

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Semantic proximity Read ↗

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.Semantic proximity Read ↗

Adaptive mutability of colorectal cancers in response to targeted therapiesSemantic proximity Read ↗

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Semantic proximity Read ↗

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Drug-induced colorectal cancer persister cells show increased mutation rateSemantic proximity Read ↗

Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer.Semantic proximity Read ↗

Mutation, cell kinetics, and subpopulations at risk for colon cancer in the United States.Semantic proximity Read ↗

Evolution of resistance during clonal expansion.Semantic proximity Read ↗

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based StudySemantic proximity Read ↗

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.Semantic proximity Read ↗

Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.